TWI289060B - Pharmaceutical composition for improving the recovery of post-stroke patients - Google Patents
Pharmaceutical composition for improving the recovery of post-stroke patients Download PDFInfo
- Publication number
- TWI289060B TWI289060B TW090104150A TW90104150A TWI289060B TW I289060 B TWI289060 B TW I289060B TW 090104150 A TW090104150 A TW 090104150A TW 90104150 A TW90104150 A TW 90104150A TW I289060 B TWI289060 B TW I289060B
- Authority
- TW
- Taiwan
- Prior art keywords
- stroke
- pharmaceutical composition
- recovery
- patient
- patients
- Prior art date
Links
- 238000011084 recovery Methods 0.000 title claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 208000006011 Stroke Diseases 0.000 title abstract description 56
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 5
- 206010036790 Productive cough Diseases 0.000 claims description 4
- 230000006378 damage Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 208000024794 sputum Diseases 0.000 claims description 4
- 210000003802 sputum Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 26
- 230000006872 improvement Effects 0.000 abstract description 12
- 238000002360 preparation method Methods 0.000 abstract description 4
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 abstract 2
- 229950004663 nefiracetam Drugs 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 16
- 238000000034 method Methods 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- -1 N-(2 Chemical class 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000010102 embolization Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000003788 cerebral perfusion Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 2
- 206010037180 Psychiatric symptoms Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000002555 anti-neurodegenerative effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000003073 embolic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- CSHJCESYHRWFCE-UHFFFAOYSA-N 2-amino-3-hydroxy-2-(5-methyl-1,2-oxazol-4-yl)propanoic acid Chemical compound CC=1ON=CC=1C(N)(CO)C(O)=O CSHJCESYHRWFCE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 206010051290 Central nervous system lesion Diseases 0.000 description 1
- 206010008088 Cerebral artery embolism Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000004503 fine granule Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 201000010759 hypertrophy of breast Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 239000003695 memory enhancer Substances 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 238000009377 nuclear transmutation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001227 oxiracetam Drugs 0.000 description 1
- IHLAQQPQKRMGSS-UHFFFAOYSA-N oxiracetam Chemical compound NC(=O)CN1CC(O)CC1=O IHLAQQPQKRMGSS-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000001769 parahippocampal gyrus Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000018406 regulation of metabolic process Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51195200A | 2000-02-23 | 2000-02-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI289060B true TWI289060B (en) | 2007-11-01 |
Family
ID=24037094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW090104150A TWI289060B (en) | 2000-02-23 | 2001-02-23 | Pharmaceutical composition for improving the recovery of post-stroke patients |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US6423739B1 (enExample) |
| EP (1) | EP1171123B1 (enExample) |
| JP (1) | JP2003523385A (enExample) |
| KR (1) | KR20010110798A (enExample) |
| CN (1) | CN1362877A (enExample) |
| AR (1) | AR030551A1 (enExample) |
| AT (1) | ATE336246T1 (enExample) |
| AU (1) | AU784418B2 (enExample) |
| BR (1) | BR0104586A (enExample) |
| CA (1) | CA2368352C (enExample) |
| DE (1) | DE60122252T2 (enExample) |
| DK (1) | DK1171123T3 (enExample) |
| ES (1) | ES2270981T3 (enExample) |
| HK (1) | HK1047038A1 (enExample) |
| ID (1) | ID30377A (enExample) |
| IL (1) | IL145799A (enExample) |
| MX (1) | MXPA01010749A (enExample) |
| NO (1) | NO321911B1 (enExample) |
| TW (1) | TWI289060B (enExample) |
| WO (1) | WO2001062246A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| EP1356812B1 (en) * | 2000-12-28 | 2009-05-13 | Hamilton Pharmaceuticals, Inc. | Medicines for treatment and prevention of neurogenic pain |
| JP2005501108A (ja) * | 2001-08-22 | 2005-01-13 | 第一製薬株式会社 | 神経変性治療におけるネフィラセタムの使用 |
| RU2205631C1 (ru) * | 2002-06-19 | 2003-06-10 | Закрытое акционерное общество "Брынцалов-А" | Ноотропное средство "ноотобрил" в форме таблеток |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| US8962676B2 (en) | 2009-10-22 | 2015-02-24 | University College Dublin, National University Of Ireland, Dublin | Causal therapy of diseases or conditions associated with CNS or PNS demyelination |
| RU2480214C1 (ru) * | 2011-09-22 | 2013-04-27 | Валентина Ивановна Ахапкина | Состав, обладающий модуляторной активностью с соразмерным влиянием, фармацевтическая субстанция (варианты), применение фармацевтической субстанции, фармацевтическая и парафармацевтическая композиция (варианты), способ получения фармацевтических составов |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2469995A (en) * | 1946-07-23 | 1949-05-10 | Schaul Martin Carl | Process for the production of food preparations from potatoes and similar farinaceoustubers |
| US3031314A (en) * | 1960-03-16 | 1962-04-24 | Carl E Hendel | Preparation of dehydrated potatoes |
| US3260607A (en) * | 1961-02-07 | 1966-07-12 | Canadian Patents Dev | Preparation of dehydrated cooked mashed potato |
| US3968265A (en) * | 1973-02-01 | 1976-07-06 | American Potato Company | Freeze-thaw stable, french fry potato product and process for producing the same |
| DE2923975A1 (de) | 1979-06-13 | 1980-12-18 | Nattermann A & Cie | Pyrrolidinone, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| DE2924011C2 (de) | 1979-06-13 | 1982-04-08 | A. Nattermann & Cie GmbH, 5000 Köln | Pyrrolidin-(2)-on-(1)-ylessigsäure-2,6,-dimethylanilid, Verfahren zur Herstellung und Arzneimittel, welche diese Verbindung enthalten |
| IT1141287B (it) | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| SK279285B6 (sk) | 1991-05-02 | 1998-09-09 | Daiichi Pharmaceutical Co. | Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin |
| US5525058A (en) | 1992-03-27 | 1996-06-11 | American Dental Technologies, Inc. | Dental treatment system |
| WO1997003485A1 (en) | 1995-07-10 | 1997-01-30 | Kodera Electronics Co., Ltd. | Device for inserting wire to be worked |
| US6107330A (en) | 1995-08-07 | 2000-08-22 | Daiichi Pharmaceutical Co., Ltd. | Inhibitor for narcotic analgesic dependence/resistance acquisition |
| JP2002241272A (ja) | 1996-07-18 | 2002-08-28 | Mitsubishi Pharma Corp | 医薬処方組成物 |
| NZ333978A (en) | 1996-07-30 | 2000-09-29 | Henkel Ecolab Gmbh & Co | Film-building agent for protecting teats and udders against infection after milking, comprising a film-forming component and disinfecting agents |
| AU727482B2 (en) | 1996-10-01 | 2000-12-14 | Daiichi Pharmaceutical Co., Ltd. | Mitochondrial membrane stabilizer |
| US6211701B1 (en) | 1996-12-16 | 2001-04-03 | Rose Research, Llc | Low power line switching circuit, device and method |
| IT1293533B1 (it) | 1997-07-14 | 1999-03-01 | Angeletti P Ist Richerche Bio | Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che |
| AU8131198A (en) | 1997-07-15 | 1999-02-10 | Daiichi Pharmaceutical Co., Ltd. | Prophylactic or therapeutic agent for amnesia |
| JPH1180027A (ja) | 1997-09-12 | 1999-03-23 | Dai Ichi Seiyaku Co Ltd | 向知性薬 |
| AR020115A1 (es) | 1998-08-06 | 2002-04-10 | Daiichi Seiyaku Co | Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos |
| CN1368882A (zh) | 1999-05-31 | 2002-09-11 | 第一制药株式会社 | 神经元死亡抑制剂 |
-
2001
- 2001-02-16 US US09/784,048 patent/US6423739B1/en not_active Expired - Fee Related
- 2001-02-21 AR ARP010100761A patent/AR030551A1/es unknown
- 2001-02-23 CN CN01800298A patent/CN1362877A/zh active Pending
- 2001-02-23 ES ES01906242T patent/ES2270981T3/es not_active Expired - Lifetime
- 2001-02-23 AU AU34145/01A patent/AU784418B2/en not_active Ceased
- 2001-02-23 MX MXPA01010749A patent/MXPA01010749A/es active IP Right Grant
- 2001-02-23 DK DK01906242T patent/DK1171123T3/da active
- 2001-02-23 EP EP01906242A patent/EP1171123B1/en not_active Expired - Lifetime
- 2001-02-23 AT AT01906242T patent/ATE336246T1/de not_active IP Right Cessation
- 2001-02-23 BR BR0104586-5A patent/BR0104586A/pt not_active Application Discontinuation
- 2001-02-23 CA CA002368352A patent/CA2368352C/en not_active Expired - Fee Related
- 2001-02-23 KR KR1020017013542A patent/KR20010110798A/ko not_active Ceased
- 2001-02-23 WO PCT/JP2001/001342 patent/WO2001062246A1/en not_active Ceased
- 2001-02-23 HK HK02108589.8A patent/HK1047038A1/zh unknown
- 2001-02-23 JP JP2001561312A patent/JP2003523385A/ja active Pending
- 2001-02-23 DE DE60122252T patent/DE60122252T2/de not_active Expired - Lifetime
- 2001-02-23 IL IL145799A patent/IL145799A/en not_active IP Right Cessation
- 2001-02-23 TW TW090104150A patent/TWI289060B/zh not_active IP Right Cessation
- 2001-02-23 ID IDW00200102283A patent/ID30377A/id unknown
- 2001-07-17 US US09/906,077 patent/US6399650B2/en not_active Expired - Fee Related
- 2001-10-22 NO NO20015162A patent/NO321911B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO321911B1 (no) | 2006-07-17 |
| US20010051653A1 (en) | 2001-12-13 |
| CN1362877A (zh) | 2002-08-07 |
| CA2368352C (en) | 2009-11-10 |
| MXPA01010749A (es) | 2002-08-20 |
| DE60122252T2 (de) | 2007-07-05 |
| AU3414501A (en) | 2001-09-03 |
| NO20015162D0 (no) | 2001-10-22 |
| ID30377A (id) | 2001-11-29 |
| KR20010110798A (ko) | 2001-12-13 |
| US6399650B2 (en) | 2002-06-04 |
| US20020055534A1 (en) | 2002-05-09 |
| IL145799A (en) | 2006-10-31 |
| DK1171123T3 (da) | 2006-12-04 |
| CA2368352A1 (en) | 2001-08-30 |
| US6423739B1 (en) | 2002-07-23 |
| ATE336246T1 (de) | 2006-09-15 |
| EP1171123A1 (en) | 2002-01-16 |
| DE60122252D1 (de) | 2006-09-28 |
| EP1171123B1 (en) | 2006-08-16 |
| NO20015162L (no) | 2001-12-21 |
| WO2001062246A1 (en) | 2001-08-30 |
| ES2270981T3 (es) | 2007-04-16 |
| HK1047038A1 (zh) | 2003-02-07 |
| JP2003523385A (ja) | 2003-08-05 |
| BR0104586A (pt) | 2002-01-08 |
| AR030551A1 (es) | 2003-08-27 |
| IL145799A0 (en) | 2002-07-25 |
| AU784418B2 (en) | 2006-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080076820A1 (en) | Method for treating neurodegeneration | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JP3464012B2 (ja) | 精神症候治療剤 | |
| TWI289060B (en) | Pharmaceutical composition for improving the recovery of post-stroke patients | |
| EP0808166A1 (fr) | Medicament destine au traitement des troubles obsessifs compulsifs, de l'apnee du sommeil, des dysfonctions sexuelles, de l'emese et du mal des transports | |
| EP1535616B1 (en) | Remedy for integration dysfunction syndrome | |
| KR100692235B1 (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
| CN116887822A (zh) | 治疗软骨发育不全的方法 | |
| EP1307195A2 (de) | Cilansetron enthaltende arzneimittel zur behandlung nicht-obstipativer männlicher ibs-patienten | |
| WO2020014072A1 (en) | Neostigmine pharmaceutical combination for treating myasthenia gravis | |
| IL230174A (en) | Pharmaceutical composition for the treatment of premature ejaculation | |
| WO2019023175A1 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA | |
| EP0868915A1 (en) | An anti-spasmodic and antiinflammatory composition containing a NSAID, pentifenone and fenpiverinium | |
| JPWO2001013911A1 (ja) | 高血圧性細動脈障害抑制剤 | |
| WO2020094592A1 (en) | Compounds for treating negative symptoms and cognitive impairments | |
| NZ249041A (en) | Use of brofaromine(4-(7-bromo-5-methoxy-2-benzofuranyl)-piperdine) for treating post-traumatic stress disorder | |
| WO2013062441A1 (ru) | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения | |
| RU2393861C1 (ru) | Композиция для лечения рассеянного склероза (варианты) | |
| JPH10287568A (ja) | アルコール依存症治療剤 | |
| JPH1053526A (ja) | 医薬組成物 | |
| TW201919597A (zh) | 利用新斯的明（neostigmine）及nk-1拮抗劑治療重症肌無力之醫藥組合物及方法 | |
| WO2004032932A1 (de) | Verwendung von 5-ht2-rezeptorantagonisten zur behandlung von schlafstörungen | |
| JPWO2000000187A1 (ja) | 排出障害治療用医薬組成物 | |
| EA012443B1 (ru) | Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |